King Pharmaceuticals Inc.

king pharmaceuticals inc. - All News and Analysis

• King Pharmaceuticals Inc. Q3 2008 Earnings Call Transcript

  Seeking Alpha - 2008-11-07

  Question-and-Answer SessionThank you, Mr. Squicciarino. The floor is now open for questions. [Operator Instructions]. Our first question is from Corey Davis from Natixis. Please go ahead. Corey Davis - Natixis Bleichroeder Thanks very much. I just wanted to ask a couple of questions about the Alpharma acquisition. Just kidding....

  Tags: FDA, Board, Chairman, Call Transcript, Earnings, Question, King Pharmaceuticals Inc., REMOXY, Corporate Governance, Federal Government, Sales Force Management, Business Operations, Corporate Law, Government, Sales, Seeking Alpha

• Earnings Preview: King Pharmaceuticals

  Seeking Alpha - 2008-11-05

  King Pharmaceuticals KG is expected to report Q3 earnings before market open Thursday, November 6, with a conference call scheduled for 11:00 am ET. Guidance Analysts are looking for a profit of 26c on revenue of $362M. The consensus is 23c to 29c for EPS, and $358.5M to $368.6M for...

  Tags: Revenue, Earnings, Consensus, Seeking Alpha, Financial Accounting, Finance, theflyonthewall.com, King Pharmaceuticals Inc., Healthcare

• King Pharmaceuticals Extends Tender Offer to Acquire Alpharma

  - 2008-10-13

  BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE: KG) today announced that it is extending its previously announced tender offer for all outstanding shares of Class A Common Stock of Alpharma Inc. (NYSE: ALO) until 5:00 pm, New York City time, on November 21, 2008, unless the offer is further extended....

  Tags: FINANCE, King Pharmaceuticals Inc., SEC, security, solicitation

• Alpharma Rejects King Pharma's Offer; What Now?

  Seeking Alpha - 2008-09-29

  The M & A Researcher submits: Alpharma ALO has announced the rejection of King Pharmaceuticals' KG unsolicited $37 per share offer as "financially inadequate." ALO has also disclosed the following with respect to third-party interest: by The M & A Researcher

  Tags: Healthcare, Alpharma Inc., King Pharmaceuticals Inc.

• King Pharmaceuticals Responds to Alpharma Inc

  - 2008-09-26

  BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE: KG) today issued the following statement in response to an announcement by Alpharma Inc. (NYSE: ALO) regarding King's offer to acquire Alpharma for $37.00 per share in cash.[TABLE OMITTED] On September 12, 2008, King Pharmaceuticals announced that it commenced a tender...

  Tags: Alpharma Inc., FINANCE, King Pharmaceuticals Inc., SEC, security, solicitation

• King Proposes Acquisition of Alpharma for $33 Per Share in Cash

  - 2008-08-22

  Represents Equity Value of $1.4 Billion Offers a Significant Premium to Alpharma Stockholders Combined Entity Would Create a Leading Specialty Pharmaceutical Company with Greater Commercialization Capabilities, Expanded Portfolio of Pain Management Products and a Strengthened Pipeline BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE: KG) announced today that...

  Tags: acquisition, King Pharmaceuticals Inc., SEC, solicitation

• King Pharmaceuticals Provides Updated Replay Information for Conference Call Regarding Proposed Acquisition of Alpharma

  - 2008-08-22

  BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE:KG) today held a conference call at 10:00 AM ET to discuss its proposal to acquire Alpharma Inc. (NYSE:ALO) for $33.00 per share in cash. Playback of the conference call and the webcast will be available for replay through the close of business...

  Tags: acquisition, King Pharmaceuticals Inc., SEC, solicitation

• Friday Options Update: LEH, SCHW, AKAM, KG, APO, TGT, ORCL, KO

  Seeking Alpha - 2008-08-22

  Rebecca Engmann Darst contributed to this report. Lehman Brothers LEH – Shares in Lehman Brothers bounded sharply out of the gate with a 10% gain to $15.09 on speculation that the firm might be bought by Korea Development Bank. The move in Lehman comes a day after respected analyst Richard...

  Tags: US Market, Akamai Technologies Inc., American Community Properties Trust, King Pharmaceuticals Inc., Coca-Cola Co., Lehman Brothers Holdings Inc., Oracle Corp., Charles Schwab & Co. Inc., Target Corp.

• Pain Therapeutics and King Pharmaceuticals Announce Final Data of REMOXY Phase III Study at World Pain Congress in Scotland

  - 2008-08-19

  GLASGOW, Scotland -- Pain Therapeutics, Inc. (NASDAQ: PTIE) and King Pharmaceuticals, Inc. (NYSE: KG) today presented the final data set of a previously announced pivotal Phase III study of REMOXY([R]), an investigational drug to treat chronic pain. The final data confirm REMOXY provides effective around-the-clock analgesia within a patented formulation...

  Tags: alcohol, Companies, FDA, formulation, Government, HEALTHCARE, King Pharmaceuticals Inc., patient, Scotland, U.S. Congress

• King Pharmaceuticals, Inc. Q2 2008 Earnings Call Transcript

  Seeking Alpha - 2008-08-07

  Question-and-Answer SessionThank you. The floor is now open for questions. [Operator Instructions]. Our first question comes from Greg Gilbert of Merrill Lynch. Please state your question. Gregory Gilbert - Merrill Lynch Thanks. Good morning. Can you give us your latest thoughts on the competitive environment in the Thrombin market...

  Tags: King Pharmaceuticals Inc.

• Earnings Preview: King Pharmaceuticals

  Seeking Alpha - 2008-08-06

  King Pharmaceuticals KG is expected to report Q2 earnings before market open Thursday Aug. 7, with a conference call scheduled for 11:00 am ET.Guidance Analysts are looking for a profit of 32c on revenue of $397.28M. The consensus is wide, 25c to 37c for EPS, and $361M to $423M for...

  Tags: Healthcare, King Pharmaceuticals Inc.

• King Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript

  Seeking Alpha - 2008-05-08

  Question-and-Answer SessionThank you, Mr. Squicciarino. [Operator Instructions]. And our first question comes from Donald Ellis from Thomas Weisel Partners. Please go ahead. Donald Ellis - Thomas Weisel Partners Thank you, and good morning. First question is regarding SKELAXIN. Year-over-year prescriptions were down about 8.5%, but the revenue reported was...

  Tags: King Pharmaceuticals Inc.

• King Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript

  Seeking Alpha - 2008-03-04

  Question-and-Answer SessionThank you Mr. Squicciarino. The floor is now open for questions. [Operator Instructions]. Our first question comes from Corey Davis. Go ahead Corey. Corey Davis - Natexis Bleichroeder Thanks very much. I had a couple... first how would you describe the pricing dynamics in the thrombin market now...

  Tags: King Pharmaceuticals Inc.

• King Pharmaceuticals Inc. Q3 2007 Earnings Call Transcript

  Seeking Alpha - 2007-11-08

  Question-and-Answer Session Operator Thank you Mr. Markison. [Operator Instructions]. Our first question comes from Adam Greene of J. P. Morgan, please go ahead. Adam Greene - J.P. Morgan Thanks good morning. First, your gross margin guidance of 72% to...

  Tags: King Pharmaceuticals Inc.

• Market Commentary on King Pharmaceuticals Inc.

  - 2007-05-16

  M2 PRESSWIRE-16 May 2007-Biotech News: Market Commentary on King Pharmaceuticals IncC1994-2007 M2 COMMUNICATIONS LTD RDATE:16052007 Market Commentary on King Pharmaceuticals Inc (NYSE:KG) King, headquartered in Bristol, Tenn., is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index...

  Tags: FINANCE, King Pharmaceuticals Inc., U.S. Department of Homeland Security

• Speak with other shareholders about: (NASDAQ: EPCT), (NASDAQ: SURG), (NASDAQ: PMTI) and (NYSE: KG) .

  - 2007-03-01

  M2 PRESSWIRE-1 March 2007-Stockwire.com: Speak with other shareholders about: (NASDAQ: EPCT), (NASDAQ: SURG), (NASDAQ: PMTI) and (NYSE: KG) .C1994-2007 M2 COMMUNICATIONS LTD RDATE:01032007 AUSTIN, TX - A very interesting indicator to look for is where the money is flowing into. We...

  Tags: Benefits, compensation, EpiCept Corp., FINANCE, King Pharmaceuticals Inc., MARKETING, Nasdaq Stock Market Inc., New York Stock Exchange, shareholder, stock

• Hot Stocks to Watch! March 1, 2007.

  - 2007-03-01

  M2 PRESSWIRE-1 March 2007-Wall Street Capital Funding LLC: Hot Stocks to Watch! March 1, 2007C1994-2007 M2 COMMUNICATIONS LTD RDATE:01032007 Weston, FLA. - Wall Street News Alert's "stocks to watch" this morning are: Lantis Laser Inc. (OTC: LLSR), EpiCept Corporation (NASDAQ: EPCT),...

  Tags: dentist, EpiCept Corp., FINANCE, Investment, King Pharmaceuticals Inc., Nasdaq Stock Market Inc., stock

• King will not Restate Financial Results and VI Technologies Granted NASDAQ Extension.

  - 2005-02-22

  M2 PRESSWIRE-22 February 2005-FNWU: King will not Restate Financial Results and VI Technologies Granted NASDAQ ExtensionC1994-2005 M2 COMMUNICATIONS LTD RDATE:22022005 City of Industry, CA -- Biotech industry news provided by Financial News USA (OTC: FNWU). King Pharmaceuticals, Inc. (NYSE: KG) reported...

  Tags: Biotechnology, FINANCE, financial, King Pharmaceuticals Inc., Nasdaq Stock Market Inc.

Additional Resources

• Actavis Acquires Kadian; Extends Specialty Drug Portfolio in U.S

  - 2008-12-30

  MORRISTOWN, N.J. -- Actavis today announced that it has acquired the brand name drug Kadian([R]) from King Pharmaceuticals for not more than USD127.5M, based on quarterly sales related milestones, ending 30 June 2010. Kadian([R]) which is an extended release morphine sulfate product, is the first originator brand product...

• Actavis Acquires Kadian(R); Extends Specialty Drug Portfolio in US

  - 2008-12-30

  Morristown, NJ, 30 December, 2008 --Actavis today announced that ithas acquired the brand name drug Kadian® from King Pharmaceuticalsfor not more than USD127.5M, based on quarterly sales relatedmilestones, ending 30 June 2010. Kadian® which is an extended release morphine sulfate product, is thefirst originator brand product to be marketed by...

• Incorporated: 1993
• CEO: Mr. Brian A. Markison